首页> 外文OA文献 >Pre-adapting parasitic phages to a pathogen leads to increased pathogen clearance and lowered resistance evolution with Pseudomonas aeruginosacystic fibrosis bacterial isolates
【2h】

Pre-adapting parasitic phages to a pathogen leads to increased pathogen clearance and lowered resistance evolution with Pseudomonas aeruginosacystic fibrosis bacterial isolates

机译:将病原体的寄生虫噬菌体预适应导致病原体清除率增加,并且与铜绿假单胞菌纤维化细菌分离物的抗性进展降低

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Recent years have seen renewed interest in phage therapy - the use of viruses to specifically kill disease-causing bacteria – because of the alarming rise in antibiotic resistance. However, a major limitation of phage therapy is the ease at with bacteria can evolve resistance to phages. Here we determined if experimental coevolution can increase the efficiency of phage therapy by limiting the resistance evolution of intermittent and chronic cystic fibrosis lung isolates to four different phages. We first pre-adapted all phage strains against all bacterial strains and then compared the efficacy of pre-adapted and non-adapted phages against ancestral bacterial strains. We found that evolved phages were more efficient in reducing bacterial densities than ancestral phages. This was primarily because only 50% of bacterial strains were able to evolve resistance to evolved phages, while all bacteria were able to evolve some level of resistance to ancestral phages. While the rate of resistance evolution did not differ between intermittent and chronic isolates, it incurred a relatively higher growth cost for chronic isolates when measured in the absence of phages. This is likely to explain why evolved phages were more effective in reducing the densities of chronic isolates. Our data shows that pathogen genotypes respond differently to phage pre-adaptation, and as a result, phage therapies might need to be individually adjusted for different patients.
机译:近年来,由于对抗生素耐药性的惊人提高,人们对噬菌体疗法重新产生了兴趣-使用病毒专门杀死引起疾病的细菌。但是,噬菌体治疗的主要局限性在于细菌容易产生对噬菌体的抗性。在这里,我们确定实验性协同进化是否可以通过将间歇性和慢性囊性纤维化肺隔离株的耐药性进化限制在四种不同的噬菌体上来提高噬菌体治疗的效率。我们首先针对所有细菌菌株预先适应所有噬菌体菌株,然后比较针对原始细菌菌株的预先适应和未适应噬菌体的功效。我们发现进化的噬菌体在降低细菌密度方面比祖先的噬菌体更有效。这主要是因为只有50%的细菌菌株能够进化出对进化噬菌体的抗性,而所有细菌都能进化出一定水平的对祖传噬菌体的抗性。虽然间歇性和慢性分离株之间耐药性进化的速率没有差异,但在不存在噬菌体的情况下,慢性分离株的抗药性增长成本相对较高。这可能可以解释为什么进化的噬菌体在降低慢性分离株的密度方面更有效。我们的数据表明,病原体基因型对噬菌体预适应的反应不同,因此,可能需要针对不同患者分别调整噬菌体治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号